37819-43-5

Basic information

• Product Name: Propanoic acid, 2-(4-bromophenoxy)-, (S)-
• CAS NO: 37819-43-5
• Molecular Formula: C9H9BrO3
• Molecular Weight: 245.073
• Mol File: 37819-43-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-(4-bromophenoxy)-, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(4-bromophenoxy)-, (S)-(37819-43-5)
• EPA Substance Registry System: Propanoic acid, 2-(4-bromophenoxy)-, (S)-(37819-43-5)

Safety Data

• Hazardous Substances Data: 37819-43-5(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 29617-66-1 (S)-2-chloropropanoic acid 
• 23849-12-9 methyl 2-(4-bromophenoxy)propanoate 

Downstream Products

• 360792-56-9 (2S)-2-(4-bromophenoxy)propylamine hydrochloride 
• 360792-00-3 (2S)-2-(4-bromophenoxy)propylamine 
• 360791-99-7 [(2S)-2-(4-bromophenoxy)propyl][(methylethyl)sulfonyl]amine 
• 16453-37-5 (2S)-2-(4-Bromophenoxy)propanamide 

Relevant articles and documents

Compounds For The Treatment Of Neuromuscular Disorders

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME

Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

Enantioselective hydrolysis of some 2-aryloxyalkanoic acid methyl esters and isosteric analogues using a penicillin G acylase-based HPLC monolithic silica column

A technique based on liquid chromatography has been developed to facilitate studies of enantioselectivity in penicillin G acylase (PGA)-catalyzed hydrolysis of some 2-aryloxyalkanoic acid methyl esters and isosteric analogues. PGA was covalently immobilized on an aminopropyl monolithic silica support to create an immobilized HPLC-enzyme reactor. Two sets of experimental data were drawn to calculate the enantioselectivity (E) of the kinetically controlled enantiomer-differentiating reaction, the degree of substrate conversion and the enantiomeric excess of the product. The developed enzymatic reactor was coupled through a switching valve to an achiral analytical column for separation and quantitation of the hydrolysis products. The enantiomeric excess was determined off-line on a PGA-chiral stationary phase. In this way, highly precise E values were determined. A computational study related to the hydrolysis of the considered racemic esters was also carried out in order to unambiguously clarify both the substrate specificity and the enantioselectivity displayed by PGA.